SBT Lead Therapeutic sdAb: SBT-100
Singh Biotechnology
SBT Lead
Therapeutic sdAb: SBT-100
SBT-100 is a bi-specific KRAS/STAT3 inhibitor
Nanomolar affinity to KRAS/STAT3 (the most common mutations)
Internalizes into cancer cells
Crosses cell membrane & BBB (Blood Brain Barrier)
In vivo & In vitro efficacy data against KRAS & STAT3 cancers
Short serum half-life but long biological half-life
No toxicity observed for 28 days
Pre-IND stage (2Q20)
Potential therapeutic for a large range of cancers
In various malignancies (pancreatic cancer and glioblastomas) KRAS & STAT3 work together to produce malignant transformation.
KRAS can promote IL-6 production in the tumor microenvironment resulting in STAT3 activation in cancer cells.
In some clinical situations KRAS via its downstream target can phosphorylate the serine residue of STAT3 to further potentiate its activation.
Targeting both KRAS & STAT3 minimizes the potential for drug resistant cancer cells from developing.
STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis.
Cancer Cells
Cancer Cells + SBT-100